"Mechanismus protin\u00E1dorov\u00E9 aktivity komplex\u016F platiny"@cs . "\u010Cesk\u00E9 Bud\u011Bjovice" . . . "Mechanism of the anti-tumor activity of platinum complexes" . . . "It is hypothesized that development of platinum compounds structurally dissimilar to cisplatin may lead to agents with a spectrum of clinical activity complementary to the parent drug. Moreover, as DNA is considered the major pharmacological target of platinum compounds, the latter hypothesis also implies that platinum agents which bind to DNA in a fundamentally different manner to that of cisplatin may have altered pharmacological properties."@en . "1"^^ . "Mechanism of the anti-tumor activity of platinum complexes" . . "1"^^ . "Advances in Cell and Molecular Biology" . . "Mechanism of the anti-tumor activity of platinum complexes"@en . . "RIV/68081707:_____/05:00022934!RIV06-AV0-68081707" . . "Mechanism of the anti-tumor activity of platinum complexes"@en . . "Byla navr\u017Eena hypot\u00E9za, \u017Ee v\u00FDvoj platinov\u00FDch slou\u010Denin strukturn\u011B odli\u0161n\u00FDch od cisplatiny m\u016F\u017Ee v\u00E9st k synt\u00E9ze l\u00E1tek, jejich\u017E spektrum klinick\u00E9 aktivity je komplement\u00E1rn\u00ED k p\u016Fvodn\u00ED cisplatin\u011B. Vzhledem k tomu, \u017Ee DNA je pova\u017Eov\u00E1na za hlavn\u00ED c\u00EDlov\u00E9 m\u00EDsto farmakologick\u00E9ho p\u016Fsoben\u00ED platinov\u00FDch slou\u010Denin, z t\u00E9to hypot\u00E9zy vypl\u00FDv\u00E1, \u017Ee platinov\u00E9 slou\u010Deniny, kter\u00E9 se v\u00E1\u017E\u00ED k DNA zp\u016Fsobem z\u00E1sadn\u011B odli\u0161n\u00FDm od cisplatiny mohou vykazovat odli\u0161n\u00E9 farmakologick\u00E9 vlastnosti."@cs . "[1D9C23E27027]" . . "80-7232-263-X" . . "Brabec, Viktor" . . "RIV/68081707:_____/05:00022934" . "18"^^ . "529350" . "DNA; cancer; platinum drugs"@en . "Kopp Publishing" . . . "Mechanismus protin\u00E1dorov\u00E9 aktivity komplex\u016F platiny"@cs . "Z(AV0Z50040507)" . "It is hypothesized that development of platinum compounds structurally dissimilar to cisplatin may lead to agents with a spectrum of clinical activity complementary to the parent drug. Moreover, as DNA is considered the major pharmacological target of platinum compounds, the latter hypothesis also implies that platinum agents which bind to DNA in a fundamentally different manner to that of cisplatin may have altered pharmacological properties." . "73;90" . .